Provide the method to identify patients who may benefit from PARPi therapy
NovoFocus™ PARPi CDx 1.0 is a next-generation sequencing (NGS)-based companion diagnostic (CDx) assay for poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) therapy in ovarian and breast cancers. BRCA1/2 mutations are highly relevant to ovarian and breast cancers. Mutations in homologous recombinant repair (HRR) genes cause homologous recombination deficiency (HRD).
Mechanism of PARP Inhibition
HRR Gene Mutation and PARPi Therapy
PARP inhibitors approved by the U.S. Food and Drug Administration (FDA):
Lynparza® (olaparib), Talzenna™ (talazoparib), Rubraca® (rucaparib) and Zejula® (niraparib) for deleterious or suspected deleterious BRCA1/2-mutated ovarian cancer and BRCA1/2 mutated, HER2-nagetive metastatic breast cancer patients.
Zejula® (niraparib) for advanced ovarian cancer which is associated with homologous recombination deficiency, including loss of heterozygosity (LOH).
NovoFocus™ PARPi CDx 1.0
14 Calendar Days
Plasma (Extracted DNA)
Novogene Quality Assurance
NovoFocus™ PARPi CDx 1.0 interrogates 45 genes. It can detect genomic abnormalities (SNV, InDel, CNV and Fusion) and homologous recombination deficiency (HRD). Besides, it provides targeted therapy options and related hereditary cancer risk assessment.
Comprehensive analytical validation has been completed and the test includes rigorous quality control measures.
With leading-edge sequencing solutions and superior process efficiency, Novogene offers highly competitive prices for all our service.
Who Benefit from NovoFocus™ PARPi CDx 1.0?
All breast cancer patients and ovarian cancer patients are highly recommended to have the test, especially for the following patients:
Note: Prostate cancer or other cancer patients can be tested according to the physicians’ suggestion.